CSPC Innovation Reports Decrease in H1 2024 Earnings
Company Announcements

CSPC Innovation Reports Decrease in H1 2024 Earnings

CSPC Pharmaceutical Group (HK:1093) has released an update.

CSPC Innovation Pharmaceutical Co., Ltd., a subsidiary of CSPC Pharmaceutical Group Limited, has released its unaudited financial results for the first half of 2024, showing a significant decrease in revenue and net profit compared to the previous year. Investors are advised to exercise caution when dealing in the company’s securities. The financial report, prepared according to Chinese accounting standards, indicates notable declines in key financial indicators such as net cash flows from operating activities and return on net assets.

For further insights into HK:1093 stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks HongKong Auto-Generated NewsdeskCSPC Pharmaceutical Group to Announce Financial Results
TipRanks HongKong Auto-Generated NewsdeskCSPC Pharmaceutical Warns of Profit Decline Amid Drug Sales Challenges
TipRanks HongKong Auto-Generated NewsdeskCSPC Pharma Advances CAR-T Therapy for Myasthenia Gravis
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App